Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NYX 104

Next Previous
Drug Profile

NYX 104

Alternative Names: NYX-104

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Noxopharm
  • Developer Noxopharm; Nyrada
  • Class Neuroprotectants
  • Mechanism of Action TRPC3 cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Neurological-disorders in Australia (Rectal, Suppository)
  • 11 May 2018 NYX 104 is available for licensing as of 27 Jan 2018. http://www.nyrada.com
  • 11 May 2018 Nyrada has patent protection for NYX 104

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top